MTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?

Transplantation Reviews

Volumn 29, Issue 2, 2015, Pages 93-102

  Holdaas, Hallvard ^a   Potena, Luciano ^b   Saliba, Faouzi ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ARTERIAL STIFFNESS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG EXPOSURE; DYSLIPIDEMIA; GRAFT RECIPIENT; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); NONHUMAN; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; DYSLIPIDEMIAS; GRAFT REJECTION; ORGAN TRANSPLANTATION;

CALCINEURIN INHIBITORS; CYCLOSPORINE; DYSLIPIDEMIAS; EVEROLIMUS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TOR SERINE-THREONINE KINASES;

EID: 84928205814     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2014.08.003     Document Type: Review

References (101)

1. Lentine K.L., Costa S.P., Weir M.P., et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2012, 126:617-663.
2. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006, 82:603-611.
3. Lentine K.L., Brennan D.C., Schnitzler M.A. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005, 16:496-506.
4. Kasiske B.L., Maclean J.R., Snyder J.J. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006, 17:900-907.
5. Guckelberger O., Mutzke F., Glanemann, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006, 12:394-401.
6. Madhwal S., Atreja A., Albeldawi M., Lopez R., Post A., Costa M.A. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012, 18:1140-1146.
7. Colvin-Adams M., Smith J.M., Heubner B.M., et al. OPTN/SRTR 2011 Annual Data Report: heart. Am J Transplant 2013, 13:119-148.
8. Stehlik J., Hosenpud J.D., Edwards L.B., Hertz M.I., Mehra M.R. International Society for Heart and Lung Transplantation. ISHLT International Registry for Heart and Lung Transplantation-into the fourth decade, from strength to strength. J Heart Lung Transplant 2013, 32:941-950.
9. Organ Procurement and Transplant Network Database Available at, [Accessed 2 October 2013]. http://optn.transplant.hrsa.gov/.
10. Fellstrom B., Jardine A.G., Soveri I., et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005, 79:1160-1163.
11. Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013, 3:263-265.
12. Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
13. Arora S., Aukrust P., Andreassen A., et al. The prognostic importance of modifiable risk factors after heart transplantation. Am Heart J 2009, 158:431-436.
14. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized, long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function and protocol compliance at one year. Transplantation 2004, 77:252-258.
15. Claes K., Meier-Kriesche H.-U., Schold J.D., Vanrenterghem Y., Halloran P.F., Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012, 27:850-857.
16. Muñoz S.J., Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005, 11:S52-S56.
17. Kirklin J.K., Benza R.L., Rayburn B.K., McGiffin D.C. Strategies for minimizing hyperlipidemia after cardiac transplantation. Am J Cardiovasc Drugs 2002, 2:377-387.
18. Escobar A., Ventura H.O., Stapleton D.D., et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994, 74:1042-1046.
19. Gaston R.S., Kasiske B.L., Fieberg A.M., et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009, 9:1811-1815.
20. Kasiske B.L., de Mattos A., Flechner S.M., et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008, 8:1384-1392.
21. Pereira M.J., Palming J., Rizell M., et al. The immunosuppressive agents rapamycin, cyclosporine A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. Mol Cell Endocrinol 2013, 365:260-269.
22. Blanchard P.G., Festuccia W.T., Houde Y.P., et al. Major involvement of mTOR in the PPAR[U+04AF]-induced stimulation of adipose tissue lipid uptake and fat accretion. J Lipid Res 2012, 53:1117-1125.
23. Ma K.L., Ruan X.Z., Powis S.H., Chen Y., Moorhead J.F., Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007, 84:1029-1036.
24. Brown N.F., Stefanovic-Racic M., Sipula I.J., Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007, 56:1500-1507.
25. Morrisett J.D., Abdel-Fattah G., Hoogeveen R., et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002, 43:1170-1180.
26. Blum C.B. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002, 2:551-559.
27. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000, 356:194-202. for The Rapamune US Study Group.
28. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280. for the Rapamune Global Study Group.
29. Legendre C., Campistol J.M., Squifflet J.P., Burke J.T. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 2003, 35:S151-S153.
30. Webster A.C., Lee V.W., Chapman J.R., Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006, 81:1234-1248.
31. Vitko S., Wlodarczyk Z., Kyllönen L., et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006, 6:531-538.
32. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004, 4:626-635.
33. Gurk-Turner C., Manitpisitkul W., Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 2012, 94:659-668.
34. Zuckermann A., Wang S.S., Epailly E., et al. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?. Transplant Rev 2013, 27:76-84.
35. Mendez R., Gonwa T., Yang H.C., et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1year. Transplantation 2005, 80:303-309.
36. Tedesco Silva H., Cibrik D., Johnston T., et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401-1413.
37. Flechner S.M., Gurkan A., Hartmann A., et al. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation 2013, 95:1233-1241.
38. Ekberg H., Bernasconi C., Nöldeke J., et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010, 25:2004-2010.
39. Büchler M., Caillard S., Barbier S., et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007, 7:2522-2531.
40. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006, 6:514-522.
41. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002, 74:1070-1076.
42. Fernandez M.L., Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr 2008, 27:1-5.
43. Holdaas H., Rostaing L., Serón D., et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011, 92:410-418.
44. Bemelman F.J., de Maar E.F., Press R.R., et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009, 88:421-428.
45. Budde K., Becker T., Arns A., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
46. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
47. Lebranchu Y., Thierry A., Toupance O., et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3months after renal transplantation: CONCEPT study. Am J Transplant 2009, 9:1115-1123.
48. Morales J.M., Grinyó J.M., Campistol J.M., et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation 2008, 86:620-622.
49. Teperman L., Moonka D., Sebastian A., et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013, 19:675-689.
50. Fischer L., Klempnauer J., Beckebaum S., et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. Am J Transplant 2012, 12:1855-1865.
51. Masetti M., Montalti R., Rompianesi G., et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010, 10:2252-2262.
52. De Simone P., Nevens F., De Carlis L., et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012, 12:3008-3020.
53. Abdelmalek M.F., Humar A., Stickel F., et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012, 12:694-705.
54. De Simone P., Metselaar H.J., Fischer L., et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009, 15:1262-1269.
55. Shenoy S., Hardinger K.L., Crippin J., et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007, 83:1389-1392.
56. Saliba F., Dharancy S., Lohro R., et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl 2011, 17:905-913.
57. Watson C.J., Gimson A.E., Alexander G.J., et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007, 13:1694-1702.
58. Andreassen A.K., Andersson B., Gustafsson F., Eiskjær H., Rådegran G., Gude E. Everolimus initiation and early withdrawal of calcineurin inhibitor therapy in de novo heart transplant recipients - a multicenter, randomized Scandinavian trial. Am J Transplant 2014, 14:1828-1838. Epublication ahead.
59. Eisen H., Kobashigawa J., Starling R.C., et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013, 13:1203-1216.
60. Lehmkuhl H.B., Arizon J., Viganò M., et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009, 88:115-122.
61. Gullestad L., Iversen M., Mortensen S.A., et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010, 89:864-872.
62. Gullestad L., Mortensen S.A., Eiskjaer H., et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010, 90:1581-1589.
63. Potena L., Prestinenzi P., Bianchi I.G., et al. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 2012, 31:565-570.
64. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
65. Costa R.A., Lansky A.J., Mintz G.S., et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005, 95:113-116.
66. Viklický O., Zou H., Müller V., Lacha J., Szabó A., Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000, 69:497-502.
67. Ma K.L., Ruan X.Z., Powis S.H., Moorhead J.F., Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007, 292:H2721-H2728.
68. Baetta R., Granata A., Canavesi M., et al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther 2009, 328:419-425.
69. Goueffic Y., Potter-Perigo S., Chan C.K., et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis 2007, 195:23-30.
70. _ mice despite severe hypercholesterolemia. Atherosclerosis 2008, 198:39-48.
71. Chen W.Q., Zhong L., Zhang L., et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009, 156:941-951.
72. Verheye S., Martinet W., Kockx M.M., et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007, 49:706-715.
73. Kobashigawa J.A., Pauly D.F., Starling R.C., et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus or mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail 2013, 1:389-399.
74. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858.
75. McKenna G.J., Trotter J.F., Klintmalm E., et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011, 11:2379-2387.
76. Flechner S.M., Kurian S.M., Solez K., et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004, 4:1776-1785.
77. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005, 45:1532-1537.
78. Verbeke F., Maréchal C., Van Laecke S., et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011, 58:833-838.
79. Bahous S.A., Blacher J., Safar M.E. Aortic stiffness, kidney disease, and renal transplantation. Curr Hypertens Rep 2009, 11:98-103.
80. Seckinger J., Sommerer C., Hinkel U.P., Hoffmann O., Zeier M., Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008, 26:2213-2219.
81. Joannidès R., Monteil C., de Ligny B.H., et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 2011, 11:2414-2422.
82. Paoletti E., Ratto E., Bellino D., Marsano L., Cassottana P., Cannella G. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. J Nephrol 2012, 25:709-718.
83. Raichlin E., Chandrasekaran K., Kremers W.K., et al. Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation 2008, 86:1395-1400.
84. Kushwaha S.S., Raichlin E., Sheinin Y., et al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J 2008, 29:2742-2750.
85. Hiemann N.E., Wellnhofer E., Lehmkuhl H.B., Knosalla C., Hetzer R., Meyer R. Everolimus prevents endomyocardial remodeling after heart transplantation. Transplantation 2011, 92:1165-1172.
86. Ekberg H., Bernasconi C., Tedesco-Silva H., et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3years after transplantation. Am J Transplant 2009, 9:1876-1885.
87. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006, 81:845-852.
88. Lebranchu Y., Snanoudj R., Toupance O., et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER Study. Am J Transplant 2012, 12:1801-1810.
89. Eisen H., Yang X. The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation. Transplantation 2006, 82:S13-S18.
90. Zeier M., Van Der Giet M. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?. Transpl Int 2011, 24:30-42.
91. Arora S., Andreassen A., Simonsen S., et al. Prognostic importance of renal function 1year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007, 84:149-154.
92. Holdaas H., Midtvedt K., Åsberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012, 11:1013-1022.
93. Kawahara T., Asthana S., Kneteman N.M. m-TOR inhibitors: what role in liver transplantation?. J Hepatol 2011, 55:1441-1451.
94. Koch M. Everolimus in liver and lung transplantation. Drugs Today (Barc) 2009, 45:11-20.
95. Manito N., Delgado J.F., Crespo-Leiro M.G., et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010, 24:129-142.
96. Diekmann F., Andrés A., Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012, 26:27-29.
97. Navaneethan S.D., Perkovic V., Johnson D.W., Nigwekar S.U., Craig J.C., Strippoli G.F. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009, 2:CD005019.
98. Palmer S.C., Craig J.C., Navaneethan S.D., Tonelli M., Pellegrini F., Strippoli G.F. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:263-275.
99. Holdaas H., Fellström B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005, 5:2929-2936.
100. Kovarik J.M., Hartmann S., Hubert M., et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002, 42:222-228.
101. Mells G., Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007, 83:1141-1150.